» Articles » PMID: 36628977

Evidence of Carotid Atherosclerosis Vulnerability Regression in Real Life From Magnetic Resonance Imaging: Results of the MAGNETIC Prospective Study

Abstract

Background Atherosclerosis vulnerability regression has been evidenced mostly in randomized clinical trials with intensive lipid-lowering therapy. We aimed to demonstrate vulnerability regression in real life, with a comprehensive quantitative method, in patients with asymptomatic mild to moderate carotid atherosclerosis on a secondary prevention program. Methods and Results We conducted a single-center prospective observational study (MAGNETIC [Magnetic Resonance Imaging as a Gold Standard for Noninvasive Evaluation of Atherosclerotic Involvement of Carotid Arteries]): 260 patients enrolled at a cardiac rehabilitation center were followed for 3 years with serial magnetic resonance imaging. Per section cutoffs (95th/5th percentiles) were derived from a sample of 20 consecutive magnetic resonance imaging scans: (1) lipid-rich necrotic core: 26% of vessel wall area; (2) intraplaque hemorrhage: 12% of vessel wall area; and (3) fibrous cap: (a) minimum thickness: 0.06 mm, (b) mean thickness: 0.4 mm, (c) projection length: 11 mm. Patients with baseline magnetic resonance imaging of adequate quality (n=247) were classified as high (n=63, 26%), intermediate (n=65, 26%), or low risk (n=119, 48%), if vulnerability criteria were fulfilled in ≥2 contiguous sections, in 1 or multiple noncontiguous sections, or in any section, respectively. Among high-risk patients, a conversion to any lower-risk status was found in 11 (17%; =0.614) at 6 months, in 16 (25%; =0.197) at 1 year, and in 19 (30%; =0.009) at 3 years. Among patients showing any degree of carotid plaque vulnerability, 21 (16%; =0.014) were diagnosed at low risk at 3 years. Conclusions This study demonstrates with a quantitative approach that vulnerability regression is common in real life. A secondary prevention program can promote vulnerability regression in asymptomatic patients in the mid to long term.

Citing Articles

Manifestations of human atherosclerosis across vascular beds.

Jovin D, Sumpio B, Greif D JVS Vasc Insights. 2025; 2.

PMID: 39822712 PMC: 11737335. DOI: 10.1016/j.jvsvi.2024.100089.

References
1.
. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995; 273(18):1421-8. View

2.
van den Bouwhuijsen Q, Vernooij M, Hofman A, Krestin G, van der Lugt A, Witteman J . Determinants of magnetic resonance imaging detected carotid plaque components: the Rotterdam Study. Eur Heart J. 2011; 33(2):221-9. DOI: 10.1093/eurheartj/ehr227. View

3.
Biondi-Zoccai G, Mastrangeli S, Romagnoli E, Peruzzi M, Frati G, Roever L . What We Have Learned from the Recent Meta-analyses on Diagnostic Methods for Atherosclerotic Plaque Regression. Curr Atheroscler Rep. 2018; 20(1):2. DOI: 10.1007/s11883-018-0709-y. View

4.
Chu B, Kampschulte A, Ferguson M, Kerwin W, Yarnykh V, OBrien K . Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke. 2004; 35(5):1079-84. DOI: 10.1161/01.STR.0000125856.25309.86. View

5.
Brinjikji W, Lehman V, Kallmes D, Rabinstein A, Lanzino G, Murad M . The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis. J Neuroradiol. 2017; 44(4):234-240. DOI: 10.1016/j.neurad.2016.12.004. View